darolutamide
Nubeqa (darolutamide) is an androgen receptor inhibitor from Bayer for prostate cancer. It blocks the receptor that drives tumour growth and is used in non-metastatic castration-resistant disease and, with androgen deprivation therapy, in metastatic hormone-sensitive disease.
This page is based on FDA prescribing information and the EMA medicine record for darolutamide, cross-checked with DailyMed and MedlinePlus; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Prostate cancer cells have an ignition switch, the androgen receptor, that hormones turn to make them grow. Hormone-depriving therapy removes the key, but the switch can still be forced. Darolutamide glues the switch shut from the inside, so no signal, however small, can turn the engine over.
In simple terms
Most prostate cancers depend on androgen hormones acting through the androgen receptor. Treatments that lower hormone levels help, but the receptor can remain active. Darolutamide binds the receptor itself and stops it from switching on growth genes. This slows or stops cancer growth, delays the appearance of metastases and is combined with standard hormone-deprivation therapy in advanced disease.
In depth
Darolutamide is a potent, selective androgen receptor antagonist that binds the receptor with high affinity, blocking androgen-induced nuclear translocation and transcription of AR-responsive genes. Its chemical structure confers low blood-brain barrier penetration, which is associated with a comparatively low rate of central nervous system adverse effects. It shows activity against several clinically relevant AR mutants and is administered alongside androgen deprivation therapy.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How darolutamide, an androgen receptor inhibitor, works
- Prostate cancer cells have an ignition switch, the androgen receptor, that hormones turn to make them grow.
- Darolutamide is a potent, selective androgen receptor antagonist that binds the receptor with high affinity, blocking androgen-induced nuclear translocation and transcription of AR-responsive genes.
- Its chemical structure confers low blood-brain barrier penetration, which is associated with a comparatively low rate of central nervous system adverse effects.
- It shows activity against several clinically relevant AR mutants and is administered alongside androgen deprivation therapy.
Target: Androgen receptor (AR)
The receptor through which male hormones drive prostate cancer cell growth; even with low testosterone, tumours can keep signalling through it unless it is blocked directly.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- Treatment of adult patients with non-metastatic castration-resistant prostate cancer
- Treatment of adult patients with metastatic castration-sensitive prostate cancer
- With docetaxel, for metastatic castration-sensitive prostate cancer
Approved uses in European Union
EMA- Treatment of adult men with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease
- Treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy
Official sources
The statements on this page trace back to these records.
- Nubeqa (darolutamide) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- DailyMed: Nubeqa (darolutamide) label
DailyMed, U.S. National Library of Medicine
- U.S. Food and Drug Administration: darolutamide prescribing information
U.S. Food and Drug Administration
- MedlinePlus: darolutamide
MedlinePlus, U.S. National Library of Medicine
- National Cancer Institute: darolutamide
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.